Clinical Trials
8
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
- Conditions
- Small-cell Lung CancerNeuroendocrine CancerProstate CancerGastrointestinal Neuroendocrine TumorMerkel Cell Carcinoma, Recurrent
- Interventions
- First Posted Date
- 2025-07-23
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- SystImmune Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT07080242
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
- Conditions
- Gastric AdenocarcinomaAdvanced Pancreatic Ductal AdenocarcinomaEsophageal AdenocarcinomaMucinous Ovarian AdenocarcinomaOther Solid Tumors
- Interventions
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- SystImmune Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT07021066
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- SystImmune Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06714591
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸UCLA Ronald Reagan Medical Center, Los Angeles, California, United States
🇺🇸Yale Cancer Center, Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States
Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
- Conditions
- Breast Cancer Stage IIIHER2-positive Metastatic Breast CancerUnresectable Breast CarcinomaHer2-PositiveHER2 Gene MutationGastroesophageal-junction CancerNon Small Cell Lung CancerEndometrial NeoplasmsPeritoneal CancerFallopian Tube Cancer
- Interventions
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- SystImmune Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06714617
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸SCRI-Denver HealthOne, Denver, Colorado, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Conditions
- Endometrial CancerCervical CancerUrothelial CarcinomaOvarian CancerGastroesophageal-junction CancerEsophageal CancerLung CancerBiliary Tract CancerBreast CancerGastric Cancer
- Interventions
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- SystImmune Inc.
- Target Recruit Count
- 280
- Registration Number
- NCT06293898
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸Sarah Cannon Research institute - Lake Nona Florida, Orlando, Florida, United States
- Prev
- 1
- 2
- Next